Safety of combination therapy with milrinone and esmolol for heart protection during percutaneous coronary intervention in acute myocardial infarction

Kian Keong Poh, Xin Xu, Mark Y. Chan, Chi Hang Lee, Edgar L. Tay, Adrian F. Low, Koo Hui Chan, Winnie Sia, Liang Qiu Tang, Huay Cheem Tan, Charles Y. Lui, Vincent Nguyen, Kenichi Fujise, Ming He Huang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: Ischemia/reperfusion injury remains an untreated clinical problem in patients with acute myocardial infarction (AMI) despite significant advances in emergent revascularization through percutaneous coronary intervention (PCI). Pharmacological intervention for infarct size reduction is unavailable. We have identified that the medications milrinone and esmolol, when administered together at the beginning of the reperfusion, significantly decrease infarct size via reducing reperfusion injury in an experimental model. The present study tested the safety of combination therapy of milrinone and esmolol (M + E) in patients with AMI. Methods: Sixteen subjects with AMI requiring PCI were consecutively recruited. M + E was intravenously infused simultaneously for 10 min started at 5 min before anticipated angioplasty balloon inflation. Another 16 consecutively recruited AMI patients requiring PCI served as a placebo arm treated per routine clinical protocol. Blood pressure (BP) and heart rate (HR) were monitored continuously during PCI. Results: M + E combination therapy resulted in a trend of non-significant reduction in BP compared with a control group. There was a modest but significant increase in HR at the later phase of M + E infusion compared with a control group. No significant cardiac arrhythmia was induced during M + E infusion. Conclusions: The combination therapy with M + E produces a minimal change in hemodynamics and appears safe as an adjunctive therapy to PCI in AMI patients. Further studies are warranted.

Original languageEnglish (US)
Pages (from-to)527-530
Number of pages4
JournalEuropean Journal of Clinical Pharmacology
Volume70
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Milrinone
Percutaneous Coronary Intervention
Myocardial Infarction
Safety
Reperfusion Injury
Heart Rate
Blood Pressure
Therapeutics
Control Groups
Balloon Angioplasty
Economic Inflation
Clinical Protocols
Cell Division
Reperfusion
Cardiac Arrhythmias
Theoretical Models
Hemodynamics
Placebos
esmolol
Pharmacology

Keywords

  • acute myocardial infarction
  • esmolol
  • milrinone
  • reperfusion injury

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)

Cite this

Safety of combination therapy with milrinone and esmolol for heart protection during percutaneous coronary intervention in acute myocardial infarction. / Poh, Kian Keong; Xu, Xin; Chan, Mark Y.; Lee, Chi Hang; Tay, Edgar L.; Low, Adrian F.; Chan, Koo Hui; Sia, Winnie; Tang, Liang Qiu; Tan, Huay Cheem; Lui, Charles Y.; Nguyen, Vincent; Fujise, Kenichi; Huang, Ming He.

In: European Journal of Clinical Pharmacology, Vol. 70, No. 5, 2014, p. 527-530.

Research output: Contribution to journalArticle

Poh, KK, Xu, X, Chan, MY, Lee, CH, Tay, EL, Low, AF, Chan, KH, Sia, W, Tang, LQ, Tan, HC, Lui, CY, Nguyen, V, Fujise, K & Huang, MH 2014, 'Safety of combination therapy with milrinone and esmolol for heart protection during percutaneous coronary intervention in acute myocardial infarction', European Journal of Clinical Pharmacology, vol. 70, no. 5, pp. 527-530. https://doi.org/10.1007/s00228-014-1650-9
Poh, Kian Keong ; Xu, Xin ; Chan, Mark Y. ; Lee, Chi Hang ; Tay, Edgar L. ; Low, Adrian F. ; Chan, Koo Hui ; Sia, Winnie ; Tang, Liang Qiu ; Tan, Huay Cheem ; Lui, Charles Y. ; Nguyen, Vincent ; Fujise, Kenichi ; Huang, Ming He. / Safety of combination therapy with milrinone and esmolol for heart protection during percutaneous coronary intervention in acute myocardial infarction. In: European Journal of Clinical Pharmacology. 2014 ; Vol. 70, No. 5. pp. 527-530.
@article{fcf1a1ad3d404b44a0b7c5ded0478fd0,
title = "Safety of combination therapy with milrinone and esmolol for heart protection during percutaneous coronary intervention in acute myocardial infarction",
abstract = "Purpose: Ischemia/reperfusion injury remains an untreated clinical problem in patients with acute myocardial infarction (AMI) despite significant advances in emergent revascularization through percutaneous coronary intervention (PCI). Pharmacological intervention for infarct size reduction is unavailable. We have identified that the medications milrinone and esmolol, when administered together at the beginning of the reperfusion, significantly decrease infarct size via reducing reperfusion injury in an experimental model. The present study tested the safety of combination therapy of milrinone and esmolol (M + E) in patients with AMI. Methods: Sixteen subjects with AMI requiring PCI were consecutively recruited. M + E was intravenously infused simultaneously for 10 min started at 5 min before anticipated angioplasty balloon inflation. Another 16 consecutively recruited AMI patients requiring PCI served as a placebo arm treated per routine clinical protocol. Blood pressure (BP) and heart rate (HR) were monitored continuously during PCI. Results: M + E combination therapy resulted in a trend of non-significant reduction in BP compared with a control group. There was a modest but significant increase in HR at the later phase of M + E infusion compared with a control group. No significant cardiac arrhythmia was induced during M + E infusion. Conclusions: The combination therapy with M + E produces a minimal change in hemodynamics and appears safe as an adjunctive therapy to PCI in AMI patients. Further studies are warranted.",
keywords = "acute myocardial infarction, esmolol, milrinone, reperfusion injury",
author = "Poh, {Kian Keong} and Xin Xu and Chan, {Mark Y.} and Lee, {Chi Hang} and Tay, {Edgar L.} and Low, {Adrian F.} and Chan, {Koo Hui} and Winnie Sia and Tang, {Liang Qiu} and Tan, {Huay Cheem} and Lui, {Charles Y.} and Vincent Nguyen and Kenichi Fujise and Huang, {Ming He}",
year = "2014",
doi = "10.1007/s00228-014-1650-9",
language = "English (US)",
volume = "70",
pages = "527--530",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Safety of combination therapy with milrinone and esmolol for heart protection during percutaneous coronary intervention in acute myocardial infarction

AU - Poh, Kian Keong

AU - Xu, Xin

AU - Chan, Mark Y.

AU - Lee, Chi Hang

AU - Tay, Edgar L.

AU - Low, Adrian F.

AU - Chan, Koo Hui

AU - Sia, Winnie

AU - Tang, Liang Qiu

AU - Tan, Huay Cheem

AU - Lui, Charles Y.

AU - Nguyen, Vincent

AU - Fujise, Kenichi

AU - Huang, Ming He

PY - 2014

Y1 - 2014

N2 - Purpose: Ischemia/reperfusion injury remains an untreated clinical problem in patients with acute myocardial infarction (AMI) despite significant advances in emergent revascularization through percutaneous coronary intervention (PCI). Pharmacological intervention for infarct size reduction is unavailable. We have identified that the medications milrinone and esmolol, when administered together at the beginning of the reperfusion, significantly decrease infarct size via reducing reperfusion injury in an experimental model. The present study tested the safety of combination therapy of milrinone and esmolol (M + E) in patients with AMI. Methods: Sixteen subjects with AMI requiring PCI were consecutively recruited. M + E was intravenously infused simultaneously for 10 min started at 5 min before anticipated angioplasty balloon inflation. Another 16 consecutively recruited AMI patients requiring PCI served as a placebo arm treated per routine clinical protocol. Blood pressure (BP) and heart rate (HR) were monitored continuously during PCI. Results: M + E combination therapy resulted in a trend of non-significant reduction in BP compared with a control group. There was a modest but significant increase in HR at the later phase of M + E infusion compared with a control group. No significant cardiac arrhythmia was induced during M + E infusion. Conclusions: The combination therapy with M + E produces a minimal change in hemodynamics and appears safe as an adjunctive therapy to PCI in AMI patients. Further studies are warranted.

AB - Purpose: Ischemia/reperfusion injury remains an untreated clinical problem in patients with acute myocardial infarction (AMI) despite significant advances in emergent revascularization through percutaneous coronary intervention (PCI). Pharmacological intervention for infarct size reduction is unavailable. We have identified that the medications milrinone and esmolol, when administered together at the beginning of the reperfusion, significantly decrease infarct size via reducing reperfusion injury in an experimental model. The present study tested the safety of combination therapy of milrinone and esmolol (M + E) in patients with AMI. Methods: Sixteen subjects with AMI requiring PCI were consecutively recruited. M + E was intravenously infused simultaneously for 10 min started at 5 min before anticipated angioplasty balloon inflation. Another 16 consecutively recruited AMI patients requiring PCI served as a placebo arm treated per routine clinical protocol. Blood pressure (BP) and heart rate (HR) were monitored continuously during PCI. Results: M + E combination therapy resulted in a trend of non-significant reduction in BP compared with a control group. There was a modest but significant increase in HR at the later phase of M + E infusion compared with a control group. No significant cardiac arrhythmia was induced during M + E infusion. Conclusions: The combination therapy with M + E produces a minimal change in hemodynamics and appears safe as an adjunctive therapy to PCI in AMI patients. Further studies are warranted.

KW - acute myocardial infarction

KW - esmolol

KW - milrinone

KW - reperfusion injury

UR - http://www.scopus.com/inward/record.url?scp=84898884502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898884502&partnerID=8YFLogxK

U2 - 10.1007/s00228-014-1650-9

DO - 10.1007/s00228-014-1650-9

M3 - Article

VL - 70

SP - 527

EP - 530

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 5

ER -